ArticleBMC plant biology2025
Discovery of Poaceae-based virion-assembly inhibitor for managing potato virus Y.
Article in BMC plant biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Evolutionary divergence and regulatory landscapes of benzoxazinoid metabolism in monocot crops.Plant cell reports · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundThe chemical management of potato virus Y (PVY)-induced viral diseases in Solanaceae crops remains a persistent challenge. Successful systemic infection and transmission of PVY depend on the formation of intact virions, suggesting that targeted inhibition of coat protein (CP)-mediated encapsidation of viral RNA could disrupt viral assembly. However, reported inhibitors capable of disrupting such a process remain scarce. The present study reports a series of analogues derived from benzoxazinoids-allelopathic secondary metabolites of Poaceae plants-and systematically evaluates their anti-PVY activity. Furthermore, the preliminary mode of action of the most potent compound to impair viral assembly is elucidated.
resultThirty-four benzoxazinoids (L1-L34) containing sulfonamide moieties were synthesized via a three-step reaction protocol and evaluated for their virucidal activity using the half-leaf local-lesion assay. Most compounds demonstrated promising inactivation potency, with derivative L5 exhibiting a lower EC
conclusionThe study successfully developed L5, a benzoxazinoid-derived compound originating from secondary metabolites of Poaceae plants, which exhibited exceptional anti-PVY activity through serving as an inhibitor of virion assembly. These findings position L5 as a promising lead compound for the rational development of novel virion assembly inhibitors targeting CP-dependent processes in PVY and related plant viruses.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.